Yahoo Finance United States Molecular Diagnostics Market Report 2024-2032 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent Technologies, Qiagen, Myriad Genetics, Abbott Laboratories, Danaher, BD & Co
U.S. Molecular Diagnostics Market
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "United States Molecular Diagnostics Market Report by Technology, Application, Product, End User, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
The United States Molecular Diagnostics Market was US$ 7.98 billion in 2023 and will reach US$ 14.01 billion by 2032, with a CAGR of 6.45% from 2024 to 2032.
Molecular diagnostics involves identifying genomic variants to aid in detecting, diagnosing, sub-classifying, prognosis, and monitoring therapy response. It utilizes techniques to analyze biological markers in the genome and proteome, examining how cells express genes as proteins. This field applies molecular biology to medical testing. It is widely used for identifying biological markers in the genome and proteome, such as detecting bacterial genes using PCR-based techniques and measuring expressed bacterial infection-specific proteins using enzyme-linked immunosorbent assay (ELISA) and proteomics.
Molecular diagnostics enable the early diagnosis of cancer, genetic disorders, and infectious diseases using PCR, sequencing, & genetic technologies. Furthermore, the region's high prevalence of infectious and chronic diseases, such as genetic diseases, STIs, and cancer, is projected to support market expansion. For instance, according to a report published by the CDC, congenital heart defects are the most prevalent congenital disability in the U.S., impacting around 1% of births annually.
Molecular diagnostics are crucial for the early detection, diagnosis, and monitoring of conditions such as cancer and infectious diseases. This has led to a shift from traditional diagnostic methods. The American Cancer Society's 'Cancer Facts & Figures 2022' reports the estimated number of new cancer cases and deaths due to cancer in the United States in 2023. It also suggests that the high incidence of cancer in the region is expected to drive the growth of the oncology molecular diagnostics market due to the increased adoption of molecular diagnostics for cancer diagnosis.
Increasing demand for patient-centric healthcare services and growing adoption of technologically advanced testing products at point-of-care facilities such as clinics, retail pharmacies, physician offices, and others are further projected to drive market expansion over the forecast period. Moreover, market players continuously develop novel POC testing products to capture market opportunities. For instance, in February 2023, Huwel Lifesciences developed a portable RT-PCR instrument to test different types of viruses. The company claimed that the test takes about 30 minutes and can be used to analyze respiratory and other infections using blood and gastrointestinal samples. Such initiatives are expected to drive the market in the years to come.
Additionally, growing government funding to enhance the development of novel test kits is anticipated to drive the market. For instance, in September 2022, Redbud Medicine raised USD 10 million in Series A funding. Federal funding also helps local and state laboratories increase their capacity and allows them to keep up with growing demand. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of the Wave platform and novel rapid testing. Molecular diagnostic test menus for infectious diseases cannot afford to be static or superficial due to the diverse nature of contagious diseases and the building resistance of causative agents.
Healthcare-associated infections are projected to increase more rapidly in the United States. This growth is linked to the rising number of HAI cases and advancements in diagnostic technology. According to a study released by the National Library of Medicine in December 2022, approximately 4% of hospitalizations in the U.S. are impacted by HAI each year. Furthermore, rising government support in the form of initiatives to reduce the incidence of infections during hospitalizations is anticipated to fuel growth over the forecast period.
Key Attributes:
Report Attribute | Details |
No. of Pages | 135 |
Forecast Period | 2023 - 2032 |
Estimated Market Value (USD) in 2023 | $7.98 Billion |
Forecasted Market Value (USD) by 2032 | $14.1 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | United States |
Companies Covered: Overview, Recent Developments, Product Portfolio & Product Launch in Last 1 Year, Revenue
F Hoffmann-la Roche Ltd
Illumina Ltd
Hologic Corporation
Agilent Technologies Inc.
Qiagen NV
Myriad Genetics
Abbott Laboratories
Danaher Corporation
Becton, Dickinson and Company
Technology - Market is divided into 6 Viewpoints
Chips and Microarrays
In Situ Hybridization
Sequencing
Mass Spectrometry (MS)
PCR
Other Technologies
Application - Market is divided into 6 Viewpoints
Pharmacogenomics
Infectious Disease
Genetic Disease Screening
Oncology
Blood Screening
Microbiology
Human Leukocyte Antigen Typing
Product - Market is divided into 3 Viewpoints
Instruments
Reagents
Other Products
End User - Market is divided into 3 Viewpoints
Hospitals
Laboratories
Other End Users
For more information about this report visit https://www.researchandmarkets.com/r/tz5vr3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
